Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/aging.202571 http://scihub22266oqcxt.onion/10.18632/aging.202571 33640878!7993675!33640878     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Aging+(Albany+NY) 2021 ; 13 (5): 6236-6246 Nephropedia Template TP {{tp|p=33640878|t=2021. Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patients |pdf=|usr=}}{{33640878}} gab.com Text Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patients JO: Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33640878 #FOAvip BACKGROUND: The immune responses, hyper-inflammation or immunosuppression, may be closely related to COVID-19 progression. We aimed to evaluate the changes of frequency of CD14(+)HLA-DR(lo/neg) MDSCs, a population of cells with potent immunosuppressive capacity, in COVID-19 patients. METHODS: The levels of CD14(+)HLA-DR(lo/neg) MDSCs were determined by flow cytometry in 27 COVID-19 patients, and their association with clinical characteristics and laboratory data were analyzed. RESULTS: The frequency of CD14(+)HLA-DR(lo/neg) MDSCs was elevated in COVID-19 patients, particularly severe patients. A follow-up comparison revealed a decline of CD14(+)HLA-DR(lo/neg) MDSCs percentages in most patients 1 day after testing negative for SARS-CoV-2 nucleic acid, but the levels of CD14(+)HLA-DR(lo/neg) MDSCs were still greater than 50.0% in 3 ICU patients 4-10 days after negative SARS-CoV-2 results. Elevated frequency of CD14(+)HLA-DR(lo/neg) MDSCs was positively correlated with oropharyngeal viral loads and length of hospital stay, while negatively correlated with lymphocyte counts and serum albumin. Moreover, strong correlations were observed between the frequency of CD14(+)HLA-DR(lo/neg) MDSCs and T cell subsets, NK cell counts, and B cell percentages. The frequency of CD14(+)HLA-DR(lo/neg) MDSCs could be used as a predictor of COVID-19 severity. CONCLUSIONS: A high frequency of CD14(+)HLA-DR(lo/neg) MDSCs, especially in severe patients, may indicate an immunoparalysis status and could be a predictor of disease severity and prognosis. Twit Text FOAVip Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patients ????Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33640878 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33640878 #FOAvip English Wikipedia <ref>{{Cite pmid|33640878}}</ref> Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patients #MMPMID33640878 Xue G; Jiang M; Zhao R; Le A; Li J Aging (Albany NY) 2021[Feb]; 13 (5): 6236-6246 PMID33640878show ga BACKGROUND: The immune responses, hyper-inflammation or immunosuppression, may be closely related to COVID-19 progression. We aimed to evaluate the changes of frequency of CD14(+)HLA-DR(lo/neg) MDSCs, a population of cells with potent immunosuppressive capacity, in COVID-19 patients. METHODS: The levels of CD14(+)HLA-DR(lo/neg) MDSCs were determined by flow cytometry in 27 COVID-19 patients, and their association with clinical characteristics and laboratory data were analyzed. RESULTS: The frequency of CD14(+)HLA-DR(lo/neg) MDSCs was elevated in COVID-19 patients, particularly severe patients. A follow-up comparison revealed a decline of CD14(+)HLA-DR(lo/neg) MDSCs percentages in most patients 1 day after testing negative for SARS-CoV-2 nucleic acid, but the levels of CD14(+)HLA-DR(lo/neg) MDSCs were still greater than 50.0% in 3 ICU patients 4-10 days after negative SARS-CoV-2 results. Elevated frequency of CD14(+)HLA-DR(lo/neg) MDSCs was positively correlated with oropharyngeal viral loads and length of hospital stay, while negatively correlated with lymphocyte counts and serum albumin. Moreover, strong correlations were observed between the frequency of CD14(+)HLA-DR(lo/neg) MDSCs and T cell subsets, NK cell counts, and B cell percentages. The frequency of CD14(+)HLA-DR(lo/neg) MDSCs could be used as a predictor of COVID-19 severity. CONCLUSIONS: A high frequency of CD14(+)HLA-DR(lo/neg) MDSCs, especially in severe patients, may indicate an immunoparalysis status and could be a predictor of disease severity and prognosis. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/diagnosis/*immunology/pathology[MESH] |Female[MESH] |HLA-DR Antigens/analysis/*immunology[MESH] |Humans[MESH] |Immune Tolerance[MESH] |Lipopolysaccharide Receptors/analysis/*immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Myeloid-Derived Suppressor Cells/immunology/*pathology[MESH] |Prognosis[MESH]Elevated frequencies of CD14(+)HLA-DR(lo/neg) MDSCs in COVID-19 patien(epmc).pdf DeepDyve Pubget Overpricing